You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The year in personalized medicine started at the White House and ended with a congressional hearing, capturing the enthusiasm and barriers in the field.
Under a national agreement, UnitedHealthcare will cover the FoundationOne genomic profiling assay in patients with metastatic stage IV non-small cell lung cancer.
The ob-gyn groups issued a statement warning that insurers' prior authorization requirements will hinder patients' access to much needed care.
Health Care Service Corporation and New York's Excellus BlueCross BlueShield will begin covering the test as medically necessary for its members.
Roche has received regulatory clearance to finalize its acquisition of Kapa Biosystems, the company announced this week.
Cigna worked with InformedDNA to come up with scenarios under which it would cover whole-exome sequencing, although it still considers whole-genome analysis investigational.
Under the agreements, members of Fortified Provider Network and Three Rivers Provider Network will now have access to Biocept's liquid biopsy tests.
Cancer Genetics will provide oncology testing services to Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield Nebraska, and WellMark.
While the overall number of oncologists who ordered the company's tests in the third quarter did not change, the frequency with which they reordered fell by about 7 percent.
The deals with Stratose, USA Managed Care Organization, and Evolutions Health Systems provides covered access to the test to more than 21 million patients.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.